Caribou Biosciences Reports Quarterly Results for Quarter Ended June 30, 2026

What Happened
Caribou Biosciences, Inc. (CRBU) filed a Form 8-K on August 13, 2026 to announce its financial results for the quarter ended June 30, 2026 and to provide a business update. The company furnished a press release as Exhibit 99.1 to the filing; the 8-K was signed by President and CEO Rachel E. Haurwitz, Ph.D.

Key Details

• Filing date: August 13, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: quarter ended June 30, 2026.
• Press release: furnished as Exhibit 99.1 and incorporated by reference in the 8-K.
• Signature: 8-K signed by Rachel E. Haurwitz, Ph.D., President and CEO.

Why It Matters
This 8-K notifies investors that Caribou has publicly released its quarterly earnings and business update; the filing itself does not include detailed financial figures in the body of the Form 8-K, so investors should review the attached press release (Exhibit 99.1) for revenue, expenses, cash position, and any operational highlights. Timely review of the press release can provide important context for holdings or trading decisions and indicate any near-term changes in guidance, partnerships, or program progress disclosed in the company’s update.